Literature DB >> 2354862

Oligodendrocyte susceptibility to injury by T-cell perforin.

N J Scolding1, J Jones, D A Compston, B P Morgan.   

Abstract

Myelin injury in multiple sclerosis (MS) appears to be immune mediated, but the mechanisms remain unidentified. It has been shown previously that oligodendrocytes, which synthesize and maintain myelin in the central nervous system (CNS), are susceptible to attack by homologous complement and that injury may be reversible when lysis is resisted by vesicular removal of membrane attack complexes. Here it is reported that oligodendrocytes are also highly susceptible to attack by T-cell perforin, and respond similarly to sublethal attack by shedding membrane vesicles. These findings imply that oligodendrocytes are vulnerable to lysis and/or reversible injury by a variety of closely related pore-forming immune effectors; following blood-brain barrier disruption, attack by one or several of these molecules may cause transient or irreversible myelin injury. Furthermore, these results provide the first indication that vesicular repair mechanisms may allow nucleated cells to recover from perforin-mediated cell injury.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2354862      PMCID: PMC1384074     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  26 in total

1.  Vesicular disruption of myelin simulated by exposure of nerve to calcium ionophore.

Authors:  W W Schlaepfer
Journal:  Nature       Date:  1977-02-24       Impact factor: 49.962

2.  Oligodendrocytes and oligodendrocyte/type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in absence of antibody.

Authors:  D R Wren; M Noble
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

Review 3.  Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects.

Authors:  B P Morgan
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

4.  Localization of the glial fibrillary acidic protein in astrocytes by immunofluorescence.

Authors:  A Bignami; L F Eng; D Dahl; C T Uyeda
Journal:  Brain Res       Date:  1972-08-25       Impact factor: 3.252

5.  Proteolytic activity and basic protein loss in and around multiple sclerosis plaques: combined biochemical and histochemical observations.

Authors:  E R Einstein; J Csejtey; K B Dalal; C W Adams; O B Bayliss; J F Hallpike
Journal:  J Neurochem       Date:  1972-03       Impact factor: 5.372

6.  Growth of a rat neuroblastoma cell line in serum-free supplemented medium.

Authors:  J E Bottenstein; G H Sato
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

7.  A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium.

Authors:  M C Raff; R H Miller; M Noble
Journal:  Nature       Date:  1983 Jun 2-8       Impact factor: 49.962

8.  Calcium ion stimulated protein kinases in myelin.

Authors:  E H Petrali; P V Sulakhe
Journal:  Prog Brain Res       Date:  1982       Impact factor: 2.453

9.  Continual breakdown and regeneration of myelin in progressive multiple sclerosis plaques.

Authors:  J W Prineas; E E Kwon; E S Cho; L R Sharer
Journal:  Ann N Y Acad Sci       Date:  1984       Impact factor: 5.691

10.  Monoclonal antibody to a plasma membrane antigen of neurons.

Authors:  G S Eisenbarth; F S Walsh; M Nirenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

View more
  12 in total

1.  Imaging Ca2+ changes in individual oligodendrocytes attacked by T-cell perforin.

Authors:  J Jones; S Frith; S Piddlesden; B P Morgan; D A Compston; A K Campbell; M B Hallett
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

2.  Killing of cells by perforin. Resistance to killing is not due to diminished binding of perforin to the cell membrane.

Authors:  J Jones; B P Morgan
Journal:  Biochem J       Date:  1991-11-15       Impact factor: 3.857

3.  Limiting and repairing the damage in multiple sclerosis.

Authors:  A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-11       Impact factor: 10.154

4.  Perforin-dependent neurologic injury in a viral model of multiple sclerosis.

Authors:  P D Murray; D B McGavern; X Lin; M K Njenga; J Leibowitz; L R Pease; M Rodriguez
Journal:  J Neurosci       Date:  1998-09-15       Impact factor: 6.167

5.  A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain.

Authors:  D C Shields; K E Schaecher; T C Saido; N L Banik
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

Review 6.  Are current immunological concepts of multiple sclerosis reflected by the immunopathology of its lesions?

Authors:  H Lassmann; K Vass
Journal:  Springer Semin Immunopathol       Date:  1995

Review 7.  Mechanism of myelin breakdown in experimental demyelination: a putative role for calpain.

Authors:  K E Schaecher; D C Shields; N L Banik
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

8.  Major histocompatibility complex class II-restricted cytotoxicity by self-myelin basic protein-reactive T-cell hybridomas: evidence for a tumour necrosis factor-independent nucleolytic mechanism.

Authors:  D C Rayner; L D Petrycky-Cox; M Diocee; E Rector
Journal:  Immunology       Date:  1993-02       Impact factor: 7.397

Review 9.  Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival.

Authors:  Cosmin A Tegla; Cornelia Cudrici; Violeta Rus; Takahiro Ito; Sonia Vlaicu; Anil Singh; Horea Rus
Journal:  J Neuroimmunol       Date:  2009-07-04       Impact factor: 3.478

10.  Inhibition of interferon-gamma signaling in oligodendroglia delays coronavirus clearance without altering demyelination.

Authors:  John M González; Cornelia C Bergmann; Chandran Ramakrishna; David R Hinton; Roscoe Atkinson; Jason Hoskin; Wendy B Macklin; Stephen A Stohlman
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.